A Bioequivalence Study of Two Formulations of HRS-1893 Tablets in Healthy Participants

Recruiting Phase 1 Interventional Study
Cardiomyopathy
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 55
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
58 (estimated)
Sponsor
Shandong Suncadia Medicine Co., Ltd. · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This study will investigate the bioequivalence between two formulations of HRS-1893 tablets. Safety and tolerability will also be assessed.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Subjects aged 18 to 55 years (inclusive), regardless of gender; 2. Body mass index (BMI) between 19 and 28 kg/m² (inclusive), with body weight ≥ 50.0 kg and \< 90.0 kg for men, and ≥ 45.0 kg and \< 90.0 kg for women; 3. No abnormalities of clinical significance are found upon…
Contacts

Wenzheng Xiong

+86-0518-82342973

wenzheng.xiong.wx10@hengrui.com

CONTACT